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 7 
Aims: We have initiated a PhD project to investigate and implement improvements of 8 
diffusion-weighted quantitative magnetic resonance imaging (DW-qMRI) and supplementary 9 
measures as biomarkers for RT response in human brain metastases. A further aim is to 10 
propose dedicated MRI sequences for radiotherapy (RT), enabling simultaneous real-time 11 
target monitoring. 12 
 13 
Background: Tumors are inhomogeneous structures and may often be divided into 14 
subregions based on cell density, perfusion, edema, hypoxia, etc. Radiation induces cellular 15 
reactions and sub-region changes during the course of RT. Thus, there is potential for finding 16 
biomarkers for microstructural changes at a cellular level to evaluate cancer treatment 17 
response earlier than anatomical changes. In a recent study, DW-MRI has been demonstrated 18 
in a clinical trial as an early biomarker of treatment response in brain metastases (Mahmood et 19 
al. 2017). However, viable-tumor summary statistics were used for evaluation, and a voxel-20 
wise approach still needs to be implemented to determine local response. Additionally, 21 
sensitivity to region-of-interest definition and choice of estimation method (Mahmood et al. 22 
2015) calls for an optimization of qMRI sequences and post-processing approaches before 23 
clinical feasibility testing. The growing role of MRI in target definition and potentially in 24 
treatment adaptation has recently resulted in commercialization of hybrid MRI – linear 25 
accelerator systems. This potentially enables daily adaptation of treatment plans based on 26 
biological information acquired with qMRI. 27 
 28 
Methods: Existing clinical trial data will be used for development of voxel-based analyses of 29 
the metastases based on multi-parametric classification/clustering methods.  Multi-parametric 30 
qMRI optimization will be pursued using simulation and sequence development tools. In 31 
particular, highly sensitive fast mapping of diffusion and relaxation parameters will be 32 
developed. Among the issues to address when sensitivity is optimized are partial volume 33 
effects, hardware imperfections, suppression of unwanted signals, and motion. Testing in 34 
phantoms and healthy volunteers is planned before patient pilot scans.  35 
 36 
Perspective: The study is expected to produce general prognostic and monitoring methods for 37 
patients with brain metastases, and potentially also other tumor sites. If individualized 38 
treatment improves local control and symptom management while not increasing side effects, 39 
quality of life will increase for these patients. Net treatment costs may also be reduced.  40 
 41 
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